Prevalence of health conditions in Jersey and their multi-morbidity



Statistics Jersey: www.gov.je/statistics

Headlines

- Of all GP patients in Jersey, 75,020 (71%) had none of the 13 long-term conditions considered in this report; 17,765 (17%) had a single long-term condition and 12,705 (12%) had two or more long-term conditions.
- Three-quarters (75%) of patients with a long-term condition had either hypertension, obesity, diabetes or a combination of the three.
- Multi-morbidity increases with age: the average age of a patient with 1 of the long-term conditions was 53 years, 2 long-term conditions 65 years, 3 long-term conditions 71 years and 4 or more long-term conditions 76 years.
- Patients with no long-term conditions see their GP on average 3 times per year; patients with 4 or more long-term conditions see their GP on average 15 times per year.

Contents

| Headlines | 1 |
|---|----|
| Introduction | 2 |
| Key definitions | 2 |
| Morbidities included in the analysis | 2 |
| GP patient population | 2 |
| All patients by number of long-term conditions | 3 |
| Patients with a single morbidity | 6 |
| Patients with more than one condition | 8 |
| Conditions likely to occur in combination with other conditions | 8 |
| Combinations of two conditions (pairs) | 9 |
| Combinations of three conditions (triads) | 10 |
| Patients with four or more conditions | 13 |
| Multi-morbidity by age | 14 |
| Multi-morbidity: individual | 15 |
| GP consultations and medication by morbidity | 16 |
| Annexes | 17 |
| Annex 1: Methodology | 17 |
| Annex 2: GPCS search criteria | 17 |
| Annex 3: comparison of populations (denominators): GPCS and Statistics Jersey Projections | |
| Annex 4: all morbidity profiles | 19 |
| Annex 5: single morbidity profiles | 21 |
| Annex 6: multi-morbidity profiles | 23 |
| Annex 7: Triad groups containing over 100 patients | 25 |

Introduction

Multi-morbidity is commonly defined as the presence of two or more chronic medical conditions in a patient. These are conditions that currently have no cure, and may be managed with drugs and other treatment. As populations age, the level of multi-morbidity is likely to increase, which will have implications for health and social care provision.

Key definitions

<u>Morbidity</u>: the state of having a long-term medical condition. In this report both **the terms morbidity and condition refer specifically to the 13 conditions listed in the following section**. Prevalence: The proportion of a population having a condition at a given point in time¹.

Morbidities included in the analysis

The analysis of multi-morbidity will depend on the number and type of morbidities to be included. Jersey incentivises GPs to record patients with 12 long-term conditions as part of the Jersey Quality Improvement Framework (JQIF). These 12 conditions are a good basis for multi-morbidity analysis: they are agreed amongst clinicians as being important, and the data is robustly recorded on the General Practitioner Central Server (GPCS).

The JQIF conditions are:

- Atrial Fibrillation (AF)
- Asthma (AST)
- Coronary Heart Disease (CHD)
- Chronic Kidney Disease (CKD)
- Chronic Obstructive Pulmonary Disease (COPD)
- Dementia (DEM)

- Diabetes (DIA)
- Heart Failure (HF)
- Hypertension (HYP)
- Mental Health Problems (MH)
- Obesity (OB)
- Stroke and Transient Ischemic Attack (STIA)

In addition to these 12 conditions, cancer (with the exception of non-melanoma skin cancer) was also included in the analysis as a serious long-term condition. For definitions of the search terms used to identify the patients on each register, please see Annex 2.

The data searches were conducted with reference to 31 December 2017.

GP patient population

Historically, the number of patients registered on the GPCS system exceeded the estimated population of the Island. This was due to some duplication when patients moved between GP practices, and a lag in identifying patients as no longer resident if they moved off-Island. More recently accuracy has improved as surgeries have focussed on removing redundant records from their databases. To further improve data quality, only those 'active' patients are included in the analysis – that is, any patient registered with a Jersey GP practice who has had a consultation within the previous 4 years, <u>or</u> who has registered with a GP surgery in the previous 6 months.


This GPCS 'active' population size and distribution was compared to Statistics Jersey's population projections. Figure 19 in Annex 3 shows Statistics Jersey's 2017 year-end population profile plotted against the GPCS active patient population from 31 December 2017. This comparison shows the overall population counts being very similar; there are some small differences in the way counts are spread between ages and sexes.

¹ Throughout this report, the date of reference is 31 December 2017; the date to which all GP Central Server (GPCS) searches were related.

All patients by number of long-term conditions

Figures from the GPCS showed 105,490 people as registered with a Jersey GP and active on 31 December 2017. Of these, 75,020 (71%) had none of the 13 long-term conditions considered in this report; 17,765 (17%) had a single long-term condition and 12,705 (12%) had two or more long-term conditions.

Figure 1: Percentage of Jersey patients with no conditions, a single condition and multiple conditions



Progressively fewer patients had a higher number of the conditions: 17,765 (17% of all patients) had a single condition; 7,545 (7%) 2 conditions; 3,175 (3%) 3 conditions and 1,985 (2%) had 4 or more conditions.






Figure 3 shows that hypertension was the most prevalent of the 13 long-term conditions analysed (15,795 patients were recorded as meeting the JQIF hypertension criteria), and dementia the least prevalent (650 patients were recorded as meeting the JQIF dementia criteria).

The lowest mean average age was seen for asthma (44 years) and mental health (53 years); dementia (83 years), heart failure (78 years) and chronic kidney disease (76 years) were the conditions with the highest.

While many long-term conditions affected males and females fairly equally, some affected one sex more than the other. Of the analysed conditions, those that were more likely to affect female patients were dementia (62% were female and 38% male) and chronic kidney disease (60% female, 40% male), whereas coronary heart disease (66% male, 34% female), diabetes (60% male, 40% female) and atrial fibrillation (59% male, 41% female) were more likely to affect males. In some of these cases, the difference in sex inequality could be attributed to the age profile of the condition (e.g. both dementia and chronic kidney disease were most prevalent amongst older patients, where there were more females than males).

Figure 3: Count and average age of Jersey GP patients with each type of morbidity (note: patients with multi-morbidity are linked to more than one condition)




Figure 4 (overleaf) shows a detailed age-sex profile for each long-term condition. Asthma was seen to affect patients in all age bands from 0-90+, with a fairly even split between males and females. In contrast, chronic kidney disease generally became prevalent after the age of 40, peaking in the 80-84 age band and affecting more females than males.




Figure 4: Age and sex profiles of patients – per condition (note: includes both single condition and multiple condition patients)

Counts below 10 have been suppressed, and all counts rounded to the nearest 5: see the data in Annex 4

Patients with a single morbidity

The majority (60%) of patients with one of the 13 conditions under consideration, had only one condition (a single morbidity). However, some conditions were more likely to occur in isolation than others. Figure 5 shows the percentage of patients with each condition <u>only</u> having that condition (i.e. they are singly morbid). For example, 63% of patients with asthma, <u>only</u> had asthma, whereas 4% of patients that had heart failure had no other conditions.







Figure 6 shows the counts and average ages of patients with each condition and <u>no additional conditions</u>. 6,060 patients had hypertension <u>only</u>, more than any other single condition. Only 35 patients that had heart failure had no other conditions. The age-sex profiles of single conditions are shown overleafin Figure 7.









Figure 7: Age and sex profiles of patients with a single condition

Counts below 10 have been suppressed, and all counts rounded to the nearest 5: see the data in Annex 5

Patients with more than one condition

Conditions likely to occur in combination with other conditions

While some conditions were more likely to occur in isolation, others were more likely to occur in combination with at least one other. Figure 8 shows the percentage of patients with each condition that had 0, 1, 2 or 3 or more <u>other</u> conditions. E.g. while only 36% of patients with asthma had additional conditions, 96% of people that had heart failure had additional conditions (i.e. had multi-morbidity).





■ 0 ■ | ■ 2 ■ 3+

Combinations of two conditions (pairs)

Considering 13 conditions gives 78 possible pairs of condition. Table 1 shows the count of patients with each pair. Note: the table includes patients with two or more conditions, therefore patients with more than two conditions will appear multiple times in the table (*e.g. a patient with diabetes, obesity and cancer will appear in the diabetes / obesity, obesity / cancer and diabetes / cancer pairings*).

Table 1: Count of patients with at least two morbidities (rounded to nearest 5)

| | atrial fibrillation | asthma | coronary heart disease | chronic kidney disease | СОРD | dementia | diabetes | heart failure | hypertension | mental health | obesity | stroke + TIA | cancer |
|---------------------------|---------------------|------------|---------------------------|---------------------------|-------|----------|----------|---------------|--------------|---------------|----------|--------------|--------|
| atrial fibrillation | | 155 | 425 | 510 | 180 | 95 | 315 | 425 | 1,270 | 15 | 445 | 280 | 160 |
| asthma | 155 | | 180 | 210 | 425 | 35 | 285 | 95 | 1,120 | 50 | 895 | 90 | 105 |
| coronary heart disease | 425 | 180 | | 570 | 300 | 120 | 565 | 335 | 1,650 | 25 | 600 | 280 | 180 |
| chronic kidney disease | 510 | 210 | 570 | | 270 | 175 | 635 | 380 | 2,150 | 55 | 610 | 315 | 200 |
| COPD | 180 | 425 | 300 | 270 | | 60 | 240 | 185 | 1,000 | 35 | 410 | 145 | 130 |
| dementia | 95 | 35 | 120 | 175 | 60 | | 95 | 70 | 390 | 15 | 50 | 110 | 25 |
| diabetes | 315 | 285 | 565 | 635 | 240 | 95 | | 230 | 2,480 | 65 | 1,490 | 255 | 195 |
| heart failure | 425 | 95 | 335 | 380 | 185 | 70 | 230 | | 640 | 10 | 235 | 150 | 70 |
| hypertension | 1,270 | 1,120 | 1,650 | 2,150 | 1,000 | 390 | 2,480 | 640 | | 155 | 4,110 | 970 | 815 |
| mental health | 15 | 50 | 25 | 55 | 35 | 15 | 65 | 10 | 155 | | 125 | 20 | 20 |
| obesity | 445 | 895 | 600 | 610 | 410 | 50 | 1,490 | 235 | 4,110 | 125 | | 255 | 255 |
| stroke + TIA | 280 | 90 | 280 | 315 | 145 | 110 | 255 | 150 | 970 | 20 | 255 | | 90 |
| cancer | 160 | 105 | 180 | 200 | 130 | 25 | 195 | 70 | 815 | 20 | 255 | 90 | |
| | High | iest num l | perofpat | ients | | | | | | Lowes | t number | ofpatien | ts |

Note – patients with 3 or more conditions will be included in more than one cell

Combinations of three conditions (triads)

Considering 13 conditions gives 286 possible condition triads. Table 3 shows the ten triads containing the largest count of patients. These triads include patients that have three <u>or more</u> conditions. Patients with more than three conditions will appear in more than one triad (*e.g. a patient with hypertension, obesity, diabetes and CKD would appear in four triad groups: the hypertension / obesity / diabetes, hypertension / diabetes / CKD, hypertension / obesity / CKD and obesity / diabetes / CKD).*

Table 2: Combinations of three conditions most likely to occur together

| Condition triad | Count of patients |
|--|-------------------|
| hypertension, obesity, diabetes | 1,050 |
| hypertension, obesity, chronic kidney disease | 565 |
| hypertension, diabetes, chronic kidney disease | 525 |
| hypertension, obesity, coronary heart disease | 440 |
| hypertension, chronic kidney disease, coronary heart disease | 435 |
| hypertension, diabetes, coronary heart disease | 400 |
| hypertension, obesity, asthma | 395 |
| hypertension, chronic kidney disease, atrial fibrillation | 395 |
| hypertension, obesity, atrial fibrillation | 350 |
| hypertension, coronary heart disease, atrial fibrillation | 295 |

(a list of all triads with patient counts over 100 can be found in Annex 7)

Figures 9, 10 and 11 (below and overleaf) show the largest 3 triads, with the count of patients in each of the constituent conditions of that triad. In total, 22,775 patients have either hypertension, obesity, diabetes or any combination of these: this represents three-quarters (75%) of all patients with at least one condition.

Figure 9: Patients with hypertension, obesity or diabetes




Figure 10: Combination of patients with hypertension, diabetes or chronic kidney disease





Figure 11: Combination of patients with hypertension, obesity or chronic kidney disease



chronic kidney disease

Figure 12 (overleaf) shows an age-sex profile for each condition, counting only patients with 2 or more (multiple) conditions.




Figure 12: Age and sex profiles of patients with more than one condition only (i.e. excluding patients with just one of the conditions) – per condition

Counts below 10 have been suppressed, and all counts rounded to the nearest 5: see the data in Annex 6


Almost 2,000 patients (see Table 3) had 4 or more of the 13 conditions under analysis.

Table 3: Count of patients with 4 or more conditions

| | Female | Male | All |
|------------------------------------|--------|-------|-------|
| Patients with 4 or more conditions | 965 | 1,020 | 1,985 |

Considering 13 conditions gives 715 possible combinations of 4 conditions (quads); 554 of these 'quads' were found in at least one patient. Figure 13 shows the ten quad combinations with the largest count of patients. These quads included patients with four <u>or more</u> conditions so some patients (those with more than 4 conditions) will appear in more than one quad (*e.g. a patient with 5 conditions will appear in 5 quads, a patient with 6 conditions will appear in 15 quads*).

Figure 13: Most prevalent combinations of four morbidities



Multi-morbidity by age

Figures 14 and 15 show how the <u>extent</u> of patients' multi-morbidity was related to age. While 5% of 5-9 year olds had a single condition, the percentage of patients with 2 morbidities reached 5% at age 45-49 and the percentage of patients with 4 or more conditions reached 6% at age band 70-74. Table 4 shows the mean average age of patients with each number of conditions.






Figure 15: Number of conditions by age (as percentage of age band)




Table 4: Average age of patients with different numbers of conditions

| Number of conditions | 0 | 1 | 2 | 3 | 4+ |
|--------------------------|----|----|----|----|----|
| Mean average age (years) | 34 | 53 | 65 | 71 | 76 |


Multi-morbidity: individual

The sections on pairs, triads and quads of conditions counted a patient if they fell into a particular pair, triad or quad, irrespective of whether or not they had any additional conditions; this meant that patients with additional conditions fell into more than one pair, triad or quad and were therefore counted multiple times.


A different way to analyse the data is to count each patient only once (e.g. a patient with heart disease, asthma and diabetes would only be counted in the combination of heart disease / asthma / diabetes: they would <u>not</u> be counted in any of the pairs (heart disease / asthma, asthma / diabetes etc.) or single conditions.

The largest groups of condition combinations are as shown in Figures 16 and 17.

Figure 16: Breakdown of all patients actively registered with a Jersey GP







GP consultations and medication by morbidity

The mean average number of face to face consultations that patients had with their GP, and the mean average number of medication issues² to patients over the previous year were analysed. The search criteria used to specify what counted as a consultation and issues of medication can be found in Annex 2. Patients with more conditions tend to have more consultations with their GP, and are issued more medication (Figure 18).





Figure 18: Mean average number of consultations and issues of medication per patient, by number of conditions

However, if the number of consultations and issues of medication are divided by the number of conditions the patient has, the count of consultations per condtion falls as the number of conditions increases (Figure 19). The number of issues of medication stays reasonably flat with increasing conditions count.

Figure 19: Mean average number of consultations and issues of medication per patient per condition



² Medication issues are the GPCS term for a course of medication being issued to a patient. The issues are restricted to a month's course, so for a patient with ongoing prescriptions, they will have 12 medication issues per drug per year.

Annexes

Annex 1: Methodology

Throughout this report, counts below 10 are suppressed (and represented with a ~ symbol).

Counts are rounded to the nearest 5.

Annex 2: GPCS search criteria

The GPCS search criteria used are as follows:

POPULATION

The search to return those currently 'active' patients is

Practice list size estimate JQIF2018 (4 years):

Includes patients from within the 'Registered Patients' parent search where:

- EITHER Patients have had a consultation in the 4 years before the search date
- **OR** Patient has a **registration history** where **GP Links Registration Status** is patient has presented, medical card received etc... and the date status added is within 6 months before the search date.

CONDITIONS

Atrial Fibrillation: AF001 - Patients are included on the atrial fibrillation register

| Asthma | AST001 - Patients included on the asthma register |
|----------------|--|
| CHD | CHD001 - Patients are included on Coronary Heart Disease Register |
| CKD | CKD005 - Patients are included on CKD register |
| COPD | COPD001 - Patients on the COPD register |
| Dementia | DEM001 - Patients on the Dementia Register |
| Diabetes | DM017 - Patients on Diabetic Register |
| Heart Failure | HF001 - Patients on Heart Failure Register |
| Hypertension | HYP001 - Patients on hypertension register |
| Mental Health | MH001 - Patients on Mental Health Register |
| Obesity | OB002 - Patients on Obesity register |
| Stroke and TIA | STIA - Patients on Stroke / TIA Register |
| Cancer | Clinical code is B0, B1, B2, B3, B4, B5, B6, Byu, Byu0, Byu1, Byu2, Byu3, Byu4, Byu5, Byu6, Byu7, Byu8, Byu9, ByuA, ByuB, ByuC, ByuD, ByuE, K1323, K01w1, 68W24, C184 |

CONSULTATIONS and MEDICATION

| Consultation | Include Consultations where: |
|-------------------|--|
| | The Date is after 1 year before the search date and before the search date AND the Type of Consultation is Emergency consultation; Extended hours consultation; face to face consultation; face to face consultation with relative / carer; GP surgery; Home visit note or Routine Consultation |
| Medication Issues | Include Medication Issues where: |
| | The Date of Issue is after 1 year before the search date and before the search date |

Annex 3: comparison of populations (denominators): GPCS and Statistics Jersey Projections

Figure 19 shows the comparison of the Jersey population profile as estimated by Statistics Jersey, against the age - sex profile of Jersey patients held on the GPCS.




Figure 19: Comparison of age profiles from GPCS and Statistics Jersey Projections at end of year 2017

Annex 4: all morbidity profiles

These tables contain the data behind the charts in Figure 4: they are counts of patients that have the 13 conditions under analysis (either as a single condition, or one of a number of conditions). Counts below 10 have been suppressed and numbers rounded to the nearest 5.

| Γ | | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|----|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| | ₹ | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 10 | 30 | 55 | 65 | 90 | 115 | 130 | 140 | 75 | 40 | 775 |
| | ST | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 25 | 35 | 70 | 70 | 75 | 100 | 135 | 110 | 85 | 745 |
| | •• | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 30 | 55 | 90 | 130 | 160 | 190 | 230 | 275 | 190 | 130 | 1,520 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|--------|
| 8 | Male | ~ | ~ | ~ | 35 | 85 | 120 | 180 | 245 | 305 | 495 | 595 | 645 | 530 | 510 | 435 | 280 | 180 | 80 | 15 | 4,735 |
| 0 | Female | ~ | ~ | ~ | 60 | 175 | 275 | 330 | 390 | 435 | 540 | 670 | 595 | 545 | 470 | 470 | 330 | 240 | 110 | 40 | 5,670 |
| | All | ~ | ~ | ~ | 95 | 260 | 395 | 510 | 635 | 740 | 1,030 | 1,260 | 1,240 | 1,070 | 980 | 910 | 610 | 425 | 190 | 60 | 10,405 |

| | | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|--|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| | т | Male | ~ | ~ | ~ | ~ | 10 | 30 | 25 | 35 | 40 | 45 | 40 | 40 | 35 | 20 | 15 | 20 | 10 | ~ | ~ | 365 |
| | Σ | Female | ~ | ~ | ~ | ~ | ~ | 20 | 20 | 30 | 35 | 35 | 45 | 35 | 30 | 25 | 30 | 25 | 20 | ~ | ~ | 375 |
| | | All | ~ | ~ | ~ | ~ | 20 | 50 | 40 | 65 | 75 | 80 | 85 | 75 | 65 | 45 | 45 | 45 | 30 | 10 | ~ | 740 |

| Γ | | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------------|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|--------|
| | ر | Male | ~ | ~ | ~ | ~ | ~ | 10 | 45 | 110 | 200 | 440 | 730 | 910 | 1,030 | 1,140 | 1,070 | 815 | 680 | 355 | 150 | 7,700 |
| | Ŧ | Female | ~ | ~ | ~ | ~ | ~ | 15 | 45 | 110 | 170 | 325 | 645 | 835 | 940 | 990 | 1,105 | 955 | 935 | 635 | 375 | 8,090 |
| | | All | ~ | ~ | ~ | ~ | 15 | 30 | 90 | 220 | 370 | 765 | 1,375 | 1,745 | 1,975 | 2,135 | 2,175 | 1,765 | 1,615 | 990 | 525 | 15,795 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| ш | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 25 | 35 | 45 | 55 | 65 | 95 | 70 | 55 | 475 |
| I | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 15 | 15 | 35 | 60 | 100 | 100 | 80 | 425 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 40 | 50 | 65 | 90 | 125 | 195 | 170 | 130 | 900 |

| Γ | | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| | ۲ | Male | ~ | ~ | ~ | 10 | 25 | 25 | 15 | 45 | 70 | 125 | 220 | 295 | 300 | 320 | 320 | 235 | 185 | 100 | 25 | 2,315 |
| | Δ | Female | ~ | ~ | ~ | ~ | 10 | 15 | 20 | 20 | 50 | 75 | 105 | 175 | 175 | 200 | 195 | 175 | 170 | 100 | 65 | 1,555 |
| | | All | ~ | ~ | ~ | 20 | 35 | 40 | 35 | 65 | 120 | 205 | 330 | 465 | 475 | 515 | 510 | 410 | 355 | 200 | 90 | 3,870 |

| Γ | | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|----|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| | Σ | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 45 | 70 | 55 | 35 | 235 |
| | ШО | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 55 | 90 | 135 | 80 | 410 |
| | - | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 55 | 100 | 160 | 190 | 115 | 650 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 40 | 75 | 105 | 120 | 160 | 170 | 145 | 130 | 65 | 25 | 1,065 |
| 0 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 30 | 60 | 75 | 115 | 145 | 155 | 130 | 120 | 65 | 40 | 950 |
| 0 | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 20 | 70 | 135 | 185 | 240 | 305 | 320 | 275 | 250 | 130 | 65 | 2,015 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| Q | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 20 | 40 | 55 | 75 | 105 | 175 | 225 | 280 | 165 | 90 | 1,255 |
| Ť | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 25 | 45 | 75 | 95 | 160 | 230 | 300 | 350 | 330 | 255 | 1,910 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 30 | 45 | 85 | 130 | 175 | 265 | 410 | 525 | 630 | 500 | 345 | 3,165 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 40 | 105 | 145 | 205 | 250 | 260 | 260 | 235 | 155 | 70 | 1,740 |
| Т | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 25 | 40 | 80 | 85 | 115 | 130 | 175 | 120 | 100 | 890 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 50 | 130 | 185 | 285 | 335 | 370 | 390 | 410 | 275 | 170 | 2,630 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|----|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| L. | Male | 40 | 145 | 175 | 145 | 160 | 130 | 145 | 175 | 200 | 235 | 260 | 200 | 140 | 125 | 105 | 80 | 55 | 25 | ~ | 2,560 |
| AS | Female | 35 | 105 | 120 | 135 | 180 | 150 | 190 | 215 | 215 | 265 | 310 | 235 | 200 | 155 | 170 | 115 | 105 | 45 | 30 | 2,985 |
| | All | 75 | 250 | 295 | 280 | 345 | 280 | 340 | 390 | 420 | 500 | 570 | 435 | 340 | 285 | 275 | 195 | 160 | 75 | 40 | 5,545 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| ш | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 30 | 55 | 75 | 105 | 140 | 175 | 195 | 205 | 110 | 65 | 1,190 |
| 4 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 25 | 45 | 60 | 95 | 130 | 180 | 155 | 110 | 830 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 35 | 70 | 100 | 150 | 200 | 275 | 325 | 385 | 265 | 175 | 2,025 |

| L | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|-----|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|
| cel | Male | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 20 | 20 | 25 | 50 | 95 | 140 | 180 | 180 | 145 | 110 | 65 | 20 | 1,075 |
| an | Female | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 25 | 40 | 60 | 90 | 95 | 110 | 125 | 120 | 95 | 80 | 45 | 30 | 940 |
| 0 | All | ~ | ~ | ~ | ~ | 10 | 10 | 20 | 40 | 65 | 80 | 140 | 190 | 250 | 305 | 300 | 240 | 190 | 105 | 50 | 2,015 |

Annex 5: single morbidity profiles

These tables contain the data behind the charts in Figure 7: they are counts of patients that have the 13 conditions under analysis as a single condition only (patients with the conditions as one of a number of conditions are excluded). Counts below 10 have been suppressed and numbers rounded to the nearest 5.

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|--------|--------|----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|---------|-------|-------|-------|-------|-----|-------|
| ∢ | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 15 | 10 | 15 | 15 | 10 | ~ | ~ | 120 |
| STIA | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 25 | 20 | ~ | 10 | 15 | ~ | ~ | 140 |
| • | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 10 | 20 | 30 | 40 | 30 | 25 | 25 | 30 | ~ | ~ | 260 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| ß | Male | ~ | ~ | ~ | 20 | 75 | 95 | 140 | 165 | 185 | 275 | 265 | 215 | 110 | 90 | 50 | 30 | ~ | ~ | ~ | 1,730 |
| 0 | Female | ~ | ~ | ~ | 50 | 145 | 245 | 275 | 300 | 290 | 345 | 330 | 205 | 140 | 120 | 70 | 35 | 15 | ~ | ~ | 2,575 |
| | All | ~ | ~ | ~ | 75 | 215 | 345 | 420 | 465 | 475 | 620 | 590 | 420 | 250 | 210 | 125 | 65 | 20 | 10 | ~ | 4,305 |
| | - | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| Η Σ | Male | ~ | ~ | ~ | ~ | 10 | 20 | 20 | 25 | 25 | 30 | 30 | 20 | 10 | ~ | ~ | ~ | ~ | ~ | ~ | 210 |
| Σ | Female | ~ | ~ | ~ | ~ | ~ | 15 | 15 | 20 | 30 | 20 | 25 | 15 | 10 | ~ | ~ | 10 | ~ | ~ | ~ | 185 |
| | All | ~ | ~ | ~ | ~ | 15 | 35 | 40 | 45 | 55 | 45 | 50 | 35 | 20 | 15 | 10 | 10 | ~ | ~ | ~ | 395 |
| | | ~Г | 05.00 | 10.14 | 15.10 | 20.24 | 25.20 | 20.24 | 25.20 | 40.44 | 45 40 | ΓΟ Γ4 | | (0.(4 | / [/ 0 | 70 74 | 75 70 | 00.04 | 05 00 | 001 | Takal |
| • | Mala | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| ЧΥР | Male | ~ | ~ | ~ | ~ | ~ | ~ | 25 | 60 | 115 | 235 | 355 | 400 | 420 | 450 | 340 | 200 | 130 | 65 | 25 | 2,840 |
| I | Female | ~ | ~ | ~ | ~ | ~ | ~ | 25 | 60 | 85 | 180 | 330 | 410 | 430 | 450 | 440 | 330 | 270 | 135 | 70 | 3,225 |
| | All | ~ | ~ | ~ | ~ | ~ | 15 | 50 | 120 | 195 | 415 | 690 | 810 | 845 | 900 | 780 | 530 | 395 | 200 | 95 | 6,060 |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 |
| 뽀 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 35 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| DIA | Male | ~ | ~ | ~ | 10 | 20 | 20 | 10 | 25 | 25 | 40 | 60 | 70 | 50 | 60 | 30 | 25 | ~ | ~ | ~ | 460 |
| ā | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 20 | 25 | 30 | 35 | 20 | 25 | 20 | 10 | 10 | ~ | ~ | 240 |
| | All | ~ | ~ | ~ | 20 | 25 | 25 | 20 | 35 | 40 | 65 | 90 | 105 | 65 | 85 | 50 | 35 | 20 | 10 | ~ | 700 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| DEM | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | ~ | 10 | ~ | ~ | 40 |
| ö | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 10 | 15 | 15 | 15 | 75 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 20 | 25 | 20 | 20 | 115 |

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|---------|--|--------------------------------|---|--------------------------------------|--------------------------------------|--------------------------------------|---|--|---|--|--|--|--|---|--|--|--|--|--|------------------------------|--|
| PD | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 35 | 40 | 40 | 35 | 35 | 20 | 15 | ~ | ~ | 275 |
| 8 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 20 | 25 | 40 | 45 | 25 | 20 | 10 | ~ | ~ | 220 |
| U | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 60 | 65 | 85 | 80 | 65 | 40 | 25 | ~ | ~ | 495 |
| | | | | | | | | | | | | | | | | | | | | | |
| - | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| CKD | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 15 | 20 | 20 | 20 | ~ | ~ | 130 |
| σ | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 25 | 20 | 30 | 30 | 35 | 25 | 25 | 10 | 235 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 20 | 20 | 35 | 30 | 45 | 50 | 55 | 45 | 35 | 15 | 365 |
| | | ~F | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 20.24 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Tetel |
| • | Mala | <5 | 05-09 | 10-14 | 13-17 | 20-24 | 23-27 | 30-34 | 33-37 | 40-44 | | | | | | | | | | 90+ | Total |
| CHD | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 45 | 45 | 45 | 50 10 | 30 | 35 | 15 | ~ | ~ | 310 |
| 0 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | | 15 | 15 | 10 | ~ | ~ | 105 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 55 | 55 | 65 | 60 | 45 | 50 | 25 | 15 | 10 | 415 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| F | Male | <5 40 | 05-09 145 | 10-14 175 | 15-19 135 | 20-24 150 | 25-29 | 30-34 120 | 35-39 1 40 | 40-44 160 | 45-49 155 | 50-54 160 | | 60-64 55 | 65-69 30 | | 75-79 10 | 80-84 ~ | 85-89 ~ | 90+ ~ | Total 1,710 |
| AST | Male Female | | | | | 150 | | | | | | | 55-59 85 110 | | 30 | 25 | 10 | | 85-89 ~ ~ | 90+ ~ ~ | 1,710 |
| AST | | 40 | 145 | 175 | 135 | | 115 | 120 | 140 | 160 | 155 | 160 | 85 | 55 | | | | ~ | ~ | ~ | 1,710 1,785 |
| AST | Female | 40 35 | 145 105 | 175 120 | 35 30 | 50 55 | 5 30 | 20 50 | 140 170 | 60 40 | 155 165 | 160 165 | 85 110 | 55 80 | 30 50 | 25 45 | 10 25 | ~ 10 | ~ ~ | ~ | 1,710 |
| AST | Female All | 40 35 | 145 105 | 175 120 | 35 30 | 50 55 | 5 30 | 20 50 | 140 170 | 60 40 | 155 165 320 45-49 | 160 165 325 50-54 | 85 110 195 55-59 | 55 80 130 60-64 | 30 50 80 65-69 | 25 45 70 70-74 | 10 25 35 75-79 | - 10 15 80-84 | ~ ~ | ~ | 1,710 1,785 3,495 Total |
| | Female All Male | 40 35 75 | 145 105 250 | 175 120 295 | 35 30 265 | 150 155 305 | 5 30 245 | 20 50 270 | 140 170 310 | 160 140 300 | 155 165 320 | 160 165 325 | 85 110 195 55-59 30 | 55 80 130 60-64 20 | 30 50 80 65-69 40 | 25 45 70 70-74 25 | 10 25 35 75-79 20 | ~ 10 15 | ~ ~ ~ | ~ ~ ~ | 1,710 1,785 3,495 Total 215 |
| AF AST | Female All | 40 35 75 | 145 105 250 | 175 120 295 | 35 30 265 | 50 55 305 | 5 30 245 | 20 50 270 | 140 170 310 | 160 140 300 | 155 165 320 45-49 | 160 165 325 50-54 15 ~ | 85 110 195 55-59 | 55 80 130 60-64 | 30 50 80 65-69 40 10 | 25 45 70 70-74 25 10 | 10 25 35 75-79 | ~ 10 15 80-84 15 ~ | ~ ~ ~ 85-89 | ~ ~ ~ | 1,710 1,785 3,495 Total 215 90 |
| | Female All Male | 40 35 75 | 145 105 250 | 175 120 295 | 35 30 265 | 50 55 305 | 5 30 245 | 20 50 270 | 140 170 310 | 160 140 300 | 155 165 320 45-49 | 160 165 325 50-54 | 85 110 195 55-59 30 | 55 80 130 60-64 20 | 30 50 80 65-69 40 | 25 45 70 70-74 25 | 10 25 35 75-79 20 | ~ 10 15 80-84 15 | ~ ~ ~ 85-89 | ~ ~ ~ | 1,710 1,785 3,495 Total 215 |
| | Female All Male Female | 40 35 75 <5~~~~~ | 145 105 250 05-09 ~ ~ ~ | 175 120 295 10-14 ~ ~ | 135 130 265 15-19 ~ ~ | 150 155 305 20-24 ~ ~ | 115 130 245 25-29 ~ ~ ~ | 120 150 270 30-34 ~ ~ | 140 170 310 35-39 ~ ~ ~ | 160 140 300 40-44 ~ 10 | 155 165 320 45-49 15 ~ 20 | 160 165 325 50-54 15 ~ 20 | 85 110 195 55-59 30 10 40 | 55 80 130 60-64 20 15 35 | 30 50 80 65-69 40 10 50 | 25 45 70 70-74 25 10 35 | 10 25 35 75-79 20 10 30 | ~ 10 15 80-84 15 ~ 25 | ~ ~ 85-89 ~ ~ 20 | ~ ~ ~ 90+ ~ ~ | 1,710 1,785 3,495 Total 215 90 305 |
| AF | Female All Male Female All | 40 35 75 <5 ~ ~ | 145 105 250 | 175 120 295 | 35 30 265 | 50 55 305 | 5 30 245 | 120 150 270 30-34 ~ ~ ~ 30-34 | 140 170 310 35-39 ~ ~ ~ 35-39 | 160 140 300 40-44 ~ 10 40-44 | 155 165 320 45-49 15 ~ 20 45-49 | 160 165 325 50-54 15 ~ 20 50-54 | 85 110 195 55-59 30 10 40 55-59 | 55 80 130 60-64 20 15 35 60-64 | 30 50 80 65-69 40 10 50 65-69 | 25 45 70 70-74 25 10 35 70-74 | 10 25 35 75-79 20 10 30 75-79 | ~ 10 15 80-84 15 ~ 25 80-84 | ~ ~ 85-89 ~ 20 85-89 | ~ ~ ~ 90+ ~ | 1,710 1,785 3,495 Total 215 90 305 Total |
| AF | Female All Male Female All Male | 40 35 75 <5~~~~~ | 145 105 250 05-09 ~ ~ ~ | 175 120 295 10-14 ~ ~ | 135 130 265 15-19 ~ ~ | 150 155 305 20-24 ~ ~ | 115 130 245 25-29 ~ ~ ~ | 120 150 270 30-34 ~ ~ | 140 170 310 35-39 ~ ~ ~ ~ 35-39 15 | 160 140 300 40-44 ~ 10 40-44 15 | 155 165 320 45-49 15 ~ 20 45-49 15 | 160 165 325 50-54 15 ~ 20 50-54 30 | 85 110 195 55-59 30 10 40 55-59 45 | 55 80 130 60-64 20 15 35 60-64 55 | 30 50 80 65-69 40 10 50 65-69 60 | 25 45 70 70-74 25 10 35 70-74 55 | 10 25 35 75-79 20 10 30 75-79 30 | ~ 10 15 80-84 15 ~ 25 80-84 15 | ~ ~ 85-89 ~ 20 85-89 ~ | ~ ~ ~ 90+ ~ ~ | 1,710 1,785 3,495 Total 215 90 305 Total 380 |
| | Female All Male Female All | 40 35 75 <5~~~~~ | 145 105 250 05-09 ~ ~ ~ | 175 120 295 10-14 ~ ~ | 135 130 265 15-19 ~ ~ | 150 155 305 20-24 ~ ~ | 115 130 245 25-29 ~ ~ ~ | 120 150 270 30-34 ~ ~ ~ 30-34 | 140 170 310 35-39 ~ ~ ~ 35-39 | 160 140 300 40-44 ~ 10 40-44 | 155 165 320 45-49 15 ~ 20 45-49 | 160 165 325 50-54 15 ~ 20 50-54 | 85 110 195 55-59 30 10 40 55-59 | 55 80 130 60-64 20 15 35 60-64 | 30 50 80 65-69 40 10 50 65-69 | 25 45 70 70-74 25 10 35 70-74 | 10 25 35 75-79 20 10 30 75-79 | ~ 10 15 80-84 15 ~ 25 80-84 | ~ ~ 85-89 ~ 20 85-89 | ~ ~ ~ 90+ ~ ~ | 1,710 1,785 3,495 Total 215 90 305 Total |

Annex 6: multi-morbidity profiles

These tables contain the data behind the charts in Figure 14: they are counts of patients that have the 13 conditions under analysis as part of a multi-morbidity (patients with only one condition are excluded). Counts below 10 have been suppressed and numbers rounded to the nearest 5.

| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|------|-----------------|------------|-------|-------|-------|------------|------------|------------|-------|-------|-------------|-------|-------|-------|------------|-------|-------|----------|-------------|-----------|-------|
| ₹ | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 40 | 50 | 80 | 100 | 115 | 125 | 75 | 40 | 655 |
| STIA | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 10 | 20 | 45 | 50 | 65 | 90 | 120 | 105 | 80 | 600 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 30 | 60 | 90 | 130 | 165 | 205 | 245 | 180 | 120 | 1,255 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| OB | Male | ~ | ~ | ~ | 10 | 15 | 25 | 40 | 80 | 120 | 220 | 330 | 430 | 420 | 420 | 385 | 250 | 170 | 75 | 15 | 3,005 |
| 0 | Female | ~ | ~ | ~ | ~ | 30 | 30 | 55 | 90 | 145 | 195 | 340 | 385 | 400 | 350 | 400 | 295 | 230 | 105 | 40 | 3,095 |
| | All | ~ | ~ | ~ | 20 | 45 | 55 | 95 | 170 | 265 | 410 | 670 | 820 | 820 | 770 | 785 | 545 | 400 | 180 | 55 | 6,100 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| Η | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 15 | 10 | 15 | 25 | 15 | ~ | 15 | ~ | ~ | ~ | 155 |
| Σ | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | ~ | 20 | 20 | 20 | 20 | 15 | 25 | 15 | 20 | ~ | ~ | 190 |
| | All | ~ | ~ | ~ | ~ | ~ | 10 | ~ | 20 | 25 | 35 | 30 | 35 | 45 | 30 | 35 | 35 | 30 | ~ | ~ | 345 |
| - | | _ | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| ЧΥР | Male | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 50 | 85 | 205 | 375 | 510 | 610 | 690 | 730 | 610 | 555 | 290 | 125 | 4,865 |
| Í | Female | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 50 | 85 | 145 | 315 | 425 | 515 | 545 | 665 | 625 | 665 | 505 | 305 | 4,870 |
| | All | ~ | ~ | ~ | ~ | ~ | 15 | 40 | 100 | 175 | 350 | 685 | 935 | 1,125 | 1,230 | 1,395 | 1,235 | 1,220 | 795 | 430 | 9,730 |
| | 1 | | | | | | | 20.24 | | 10 11 | 45 40 | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| 보 | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 25 | 35 | 45 | 55 | 65 | 95 | 65 | 50 | 455 |
| - | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 15 | 35 | 60 | 95 | 100 | 75 | 410 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 45 | 60 | 90 | 120 | 195 | 165 | 130 | 865 |
| | | <u>د ا</u> | 05.00 | 10.14 | 15.10 | 20.24 | 25.20 | 20.24 | 25.20 | 40.44 | 45 40 | | | 10.11 | 15 /0 | 70.74 | 75 70 | 00.04 | 05.00 | 001 | |
| | Mala | <5 | 05-09 | 10-14 | 15-19 | 20-24 ~ | 25-29 ~ | 30-34 ~ | 35-39 | 40-44 | 45-49 or | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 or | 90+ 25 | Total |
| DIA | Male | ~ | ~ | ~ | ~ | ~ | ~ | | 20 | 45 | 85 | 160 | 225 | 250 | 260 | 285 | 215 | 175 | 95 | 25 | 1,855 |
| | Female | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 10 | 30 | 50 | 75 | 140 | 160 | 170 | 175 | 160 | 155 | 95 190 | 65 | 1,315 |
| | All | ~ | ~ | ~ | ~ | ~ | 10 | 20 | 30 | 75 | 135 | 235 | 365 | 410 | 430 | 460 | 375 | 335 | 190 | 90 | 3,170 |
| r | | <u> </u> | 05.00 | 10.14 | 15 10 | 20.24 | 25-29 | 20.24 | 25.20 | 10 14 | AE 40 | E0 E4 | FF FO | (0 (4 | (5 (0 | 70 74 | 75 70 | 00.04 | 0F 00 | 90+ | Total |
| - | Mala | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 ~ | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| DEM | Male Earrala | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | | 10 | 35 | 60 75 | 50 | 30 | 200 |
| □ | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 25 | 45 | 75 | 120 | 65 | 335 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 75 | 135 | 170 | 95 | 535 |

| • | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
|------|--------|----|-------|-------|-------|-------|-------|-------|-------|----------|----------|----------|------------|------------|-----------|-----------|------------|-----------|----------|----------|-------|
| PD | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 40 | 65 | 80 | 125 | 135 | 125 | 115 | 60 | 20 | 790 |
| 8 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 35 | 50 | 75 | 95 | 125 | 110 | 105 | 65 | 35 | 730 |
| U | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 75 | 120 | 155 | 225 | 260 | 230 | 220 | 125 | 55 | 1,520 |
| | | | | | | | | | | | | | | | | | | | | | |
| _ | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| CKD | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 45 | 65 | 90 | 160 | 205 | 260 | 160 | 85 | 1,125 |
| σ | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 10 | 15 | 30 | 50 | 80 | 130 | 200 | 265 | 325 | 305 | 245 | 1,675 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 15 | 30 | 65 | 95 | 145 | 220 | 360 | 470 | 585 | 465 | 330 | 2,800 |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| • | Mala | - | 05-09 | 10-14 | 13-17 | 20-24 | 23-27 | 30-34 | | | | | | | | | | | | | |
| £ | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 25 | 60 | 100 | 160 | 200 | 230 | 220 | 220 | 150 | 60 05 | 1,425 |
| 0 | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~~~~~ | ~ | ~ | 15 | 30 30 | 65 220 | 70 275 | 100 | 120 340 | 165 | 115 | 95 | 790 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 35 | 75 | 130 | 220 | 275 | 325 | 340 | 385 | 265 | 155 | 2,215 |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| F | Male | ~ | ~ | ~ | ~ | 10 | 15 | 25 | 35 | 40 | 80 | 100 | 115 | 90 | 95 | 85 | 70 | 50 | 20 | ~ | 850 |
| AST | Female | ~ | ~ | ~ | ~ | 25 | 20 | 40 | 45 | 75 | 100 | 145 | 125 | 120 | 105 | 125 | 95 | 90 | 45 | 30 | 1,200 |
| | All | ~ | ~ | ~ | 15 | 35 | 35 | 65 | 80 | 115 | 180 | 245 | 245 | 210 | 205 | 210 | 160 | 145 | 65 | 35 | 2,050 |
| | | | | | | | | | | | | | | | | | | | | | |
| | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| ш | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 35 | 45 | 85 | 105 | 155 | 175 | 190 | 100 | 65 | 980 |
| AF | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 | 15 | 30 | 50 | 85 | 120 | 170 | 145 | 110 | 740 |
| | All | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 20 | 50 | 60 | 115 | 155 | 240 | 295 | 360 | 245 | 170 | 1,720 |
| | | | | | | | | | | | | | | | | | | | | | |
| cer | | <5 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90+ | Total |
| e | Male | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 15 | 50 | 85 | 120 | 125 | 115 | 95 | 55 | 20 | 695 |
| 2 | i laic | | | | | | | | | | | | | | | | | | | | |
| Canc | Female | ~ | ~ | ~ | ~ | ~ | ~ | ~ | ~ | 10 15 | 15 20 | 30 45 | 30 80 | 60 40 | 60 180 | 80 205 | 75 190 | 70 165 | 35 90 | 30 45 | 500 |

15 20

30 45

30 80

140

60 180

80 205

75 190

70 165

35 90

30 45

1,195

10 15

Female All

Annex 7: Triad groups containing over 100 patients

| | |
|--|-------------|
| Triad combination | Count of |
| | patients |
| Hypertension, | 1,050 |
| Obesity, | 1,050 |
| Diabetes | |
| Hypertension, | 565 |
| Obesity, | 505 |
| Chronic kidney disease | |
| Hypertension, | 525 |
| Diabetes, | 010 |
| Chronic kidney disease | |
| Hypertension, | 440 |
| Obesity, | |
| Coronary heart disease | |
| Hypertension, | 435 |
| Chronic kidney disease, | |
| Coronary heart disease | |
| Hypertension, | 400 |
| Diabetes, | |
| Coronary heart disease | |
| Hypertension, | 395 |
| Obesity, | |
| Asthma | |
| Hypertension, | 395 |
| Chronic kidney disease, | |
| Atrial fibrillation | |
| Hypertension, | 350 |
| Obesity, | |
| Atrial fibrillation | |
| Hypertension, | 295 |
| Coronary heart disease, | |
| Atrial fibrillation | |
| Hypertension, | 280 |
| Atrial fibrillation, | |
| Heart failure | 270 |
| Hypertension, | 270 |
| Obesity, | |
| COPD | 200 |
| Hypertension, | 260 |
| Chronic kidney disease, | |
| Heart failure | 255 |
| Hypertension, Chronic kidney disease, | 255 |
| Stroke and TIA | |
| Obesity, | 240 |
| Diabetes, | 240 |
| Chronic kidney disease | |
| Hypertension, | 225 |
| Diabetes, | 225 |
| Atrial fibrillation | |
| | [|

| Hypertension, Obesity, Stroke and TIA220Hypertension, Coronary heart disease, Heart failure220Obesity, Diabetes, Coronary heart disease220Diabetes, Coronary heart disease, Stroke and TIA215Hypertension, Coronary heart disease, Stroke and TIA215Hypertension, Coronary heart disease, Stroke and TIA195Hypertension, Coronary heart disease, Stroke and TIA195Hypertension, Coronary heart disease, Stroke and TIA195Hypertension, Coronary heart disease, Stroke and TIA190Astma, COPD190Chronic kidney disease, COPD185Chronic kidney disease, COPD185Coronary heart disease, COPD185Hypertension, Coronary heart disease, COPD185Hypertension, Coronary heart disease, COPD185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Hypertension, Diabetes, Stroke and TIA180Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA170 | Triad combination | Count of |
|---|-------------------------|-------------|
| Obesity, Stroke and TIAHypertension, Coronary heart disease, Heart failureObesity, | | |
| Stroke and TIAHypertension,220Coronary heart disease,220Diabetes,220Diabetes,220Diabetes,215Coronary heart disease215Coronary heart disease,215Stroke and TIA195Atrial fibrillation,195Atrial fibrillation,195Obesity,20Diabetes,195Atrial fibrillation,195Obesity,20Cancer190Hypertension,190Asthma,190COPD185Atrial fibrillation,185Chronic kidney disease,185Chronic kidney disease,20COPD185Coronary heart disease,20COPD185Hypertension,185Diabetes,180Obesity,180Diabetes,180Diabetes,175Diabetes,175Diabetes,170 | Hypertension, | 220 |
| Hypertension, Coronary heart disease, Heart failure220Obesity, Diabetes, Coronary heart disease220Hypertension, Coronary heart disease, Stroke and TIA215Hypertension, Atrial fibrillation, Stroke and TIA195Hypertension, Atrial fibrillation, Stroke and TIA195Hypertension, Obesity, Cancer195Hypertension, Obesity, Cancer190Asthma, COPD190Asthma, COPD185Chronic kidney disease, Atrial fibrillation, Heart failure185Hypertension, Obesity, Coronary heart disease, COPD185Coronary heart disease, COPD185Hypertension, Chronic kidney disease, COPD185Hypertension, Coronary heart disease, COPD185Hypertension, Diabetes, Stroke and TIA180Obesity, Heart failure180Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175 | Obesity, | |
| Coronary heart disease, Heart failure220Diabetes, Coronary heart disease215Coronary heart disease, Stroke and TIA215Hypertension, Atrial fibrillation, Stroke and TIA195Hypertension, Atrial fibrillation, Stroke and TIA195Hypertension, Obesity, Cancer195Hypertension, Obesity, Cancer190Asthma, COPD190Chronic kidney disease, Atrial fibrillation, Heart failure185Hypertension, Coronary heart disease, COPD185Chronic kidney disease, COPD185Coronary heart disease, COPD185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Diabetes, Stroke and TIA180Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Asthma175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175 | Stroke and TIA | |
| Heart failureObesity,220Diabetes,215Coronary heart disease215Coronary heart disease,215Coronary heart disease,3Stroke and TIA195Hypertension,195Atrial fibrillation,195Obesity,2Cancer190Hypertension,190Asthma,190COPD2Chronic kidney disease,185Atrial fibrillation,185Chronic kidney disease,185Chronic kidney disease,2000COPD185Coronary heart disease,2000COPD185Diabetes,185Diabetes,180Obesity,180Diabetes,180Diabetes,180Diabetes,180Diabetes,170Diabetes,170 | Hypertension, | 220 |
| Obesity, Diabetes, Coronary heart disease220Diabetes, Coronary heart disease, Stroke and TIA215Hypertension, Atrial fibrillation, Stroke and TIA195Hypertension, Obesity, Cancer195Hypertension, CoPD190Asthma, COPD190Asthma, COPD185Atrial fibrillation, Heart failure185Hypertension, Coronic kidney disease, COPD185Chronic kidney disease, COPD185Coronary heart disease, COPD185Hypertension, Coronary heart disease, COPD185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA180Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA170 | Coronary heart disease, | |
| Diabetes, Coronary heart diseaseHypertension, Coronary heart disease, Stroke and TIAHypertension, Atrial fibrillation, Stroke and TIAHypertension, Obesity, CancerHypertension, COPDChronic kidney disease, Atrial fibrillation, Heart failureHypertension, COPDChronic kidney disease, COPDChronic kidney disease, COPDHypertension, Coronary heart disease, COPDHypertension, Chronic kidney disease, COPDHypertension, Chronic kidney disease, COPDHypertension, Chronic kidney disease, COPDHypertension, Chronic kidney disease, COPDHypertension, Chronic kidney disease, COPDHypertension, Diabetes, AsthmaHypertension, Diabetes, Stroke and TIAHypertension, Diabetes, Stroke and TIAHypertension, <br< td=""><td>Heart failure</td><td></td></br<> | Heart failure | |
| Coronary heart diseaseHypertension,215Coronary heart disease,Stroke and TIAHypertension,195Atrial fibrillation,Stroke and TIAHypertension,195Obesity,CancerHypertension,190Asthma,COPDChronic kidney disease,185Atrial fibrillation,Heart failureHypertension,185COPDChronic kidney disease,COPDCoPDHypertension,185Coronary heart disease,COPDHypertension,185Coronary heart disease,COPDHypertension,185Diabetes,AsthmaHypertension,185Diabetes,180Obesity,Heart failureHypertension,180Diabetes,Stroke and TIAHypertension,180Diabetes,170Diabetes,175Diabetes,170 | Obesity, | 220 |
| Hypertension, Coronary heart disease, Stroke and TIA215Hypertension, Atrial fibrillation, Stroke and TIA195Hypertension, Obesity, Cancer195Hypertension, Cancer190Hypertension, CoPD190Asthma, COPD190Chronic kidney disease, Atrial fibrillation, Heart failure185Hypertension, Chronic kidney disease, COPD185Chronic kidney disease, COPD185Chronic kidney disease, COPD185Hypertension, Coronary heart disease, COPD185Diabetes, Asthma180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Hypertension, Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA175Diabetes, Stroke and TIA170 | | |
| Coronary heart disease, Stroke and TIAHypertension,195Atrial fibrillation, Stroke and TIA195Hypertension,195Obesity, Cancer190Asthma, COPD190Asthma, COPD185Atrial fibrillation, Heart failure185Hypertension,185Chronic kidney disease, COPD185Chronic kidney disease, COPD185Chronic kidney disease, COPD185Chronic kidney disease, COPD185Diabetes, Asthma185Diabetes, Asthma180Obesity, Heart failure180Diabetes, Stroke and TIA180Diabetes, Stroke and TIA175Diabetes, COPD170 | Coronary heart disease | |
| Stroke and TIAHypertension,195Atrial fibrillation,195Stroke and TIA195Obesity,195Obesity,190Asthma,190Asthma,190CoPD185Atrial fibrillation,185Atrial fibrillation,185Chronic kidney disease,185Chronic kidney disease,185CoPD185Chronic kidney disease,2000COPD185Coronary heart disease,2000COPD185Diabetes,185Diabetes,180Obesity,180Diabetes,180Diabetes,180Diabetes,180Diabetes,175Diabetes,175Diabetes,170 | | 215 |
| Hypertension, Atrial fibrillation, Stroke and TIA195Atrial fibrillation, Stroke and TIA195Obesity, Cancer190Asthma, COPD190Asthma, COPD185Atrial fibrillation, Heart failure185Hypertension, Chronic kidney disease, COPD185Chronic kidney disease, COPD185Chronic kidney disease, COPD185Coronary heart disease, COPD185Diabetes, Asthma185Diabetes, Asthma180Obesity, Heart failure180Obesity, Heart failure180Diabetes, Stroke and TIA175Diabetes, COPD170 | | |
| Atrial fibrillation, Stroke and TIAHypertension,195Obesity, Cancer190Hypertension,190Asthma, COPD190Chronic kidney disease, Atrial fibrillation, Heart failure185Hypertension, Chronic kidney disease, COPD185Chronic kidney disease, COPD185Chronic kidney disease, COPD185Hypertension, Coronary heart disease, COPD185Diabetes, Asthma185Diabetes, Asthma180Obesity, Heart failure180Diabetes, Stroke and TIA175Diabetes, COPD170 | Stroke and TIA | |
| Stroke and TIA195Hypertension,195Obesity,190Cancer190Asthma,190Asthma,180COPD185Atrial fibrillation,185Hypertension,185Chronic kidney disease,2000COPD185Chronic kidney disease,2000COPD185Coronary heart disease,2000COPD185Diabetes,185Diabetes,180Obesity,180Ubesity,180Diabetes,180Diabetes,180Diabetes,180Diabetes,180Diabetes,170 | | 195 |
| Hypertension,195Obesity,190Cancer190Asthma,200COPD185Atrial fibrillation,185Heart failure185Hypertension,185Chronic kidney disease,200COPD185Coronary heart disease,200COPD185Diabetes,185Diabetes,185Diabetes,180Obesity,180Diabetes,180Diabetes,180Diabetes,180Diabetes,180Diabetes,175Diabetes,175Diabetes,170 | | |
| Obesity, Cancer190Hypertension, Asthma, COPD190Asthma, COPD185Chronic kidney disease, Atrial fibrillation, Heart failure185Hypertension, Chronic kidney disease, COPD185Coronary heart disease, COPD185Diabetes, Asthma185Diabetes, Asthma185Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | | |
| CancerHypertension,190Asthma,190Asthma,180COPD185Atrial fibrillation,185Atrial fibrillation,185Heart failure185Chronic kidney disease,0COPD185Coronary heart disease,0COPD185Diabetes,185Diabetes,185Diabetes,180Obesity,180Haart failure180Diabetes,180Diabetes,180Diabetes,180Diabetes,175Diabetes,175Diabetes,170 | | 195 |
| Hypertension,190Asthma,190Asthma,185COPD185Atrial fibrillation,185Heart failure185Hypertension,185Chronic kidney disease,2000COPD185Coronary heart disease,2000COPD185Diabetes,185Diabetes,185Diabetes,180Obesity,180Hypertension,180Diabetes,180Diabetes,180Diabetes,180Diabetes,175Diabetes,175Diabetes,170 | | |
| Asthma, COPD185Atrial fibrillation, Heart failure185Hypertension, Chronic kidney disease, COPD185Chronic kidney disease, COPD185Coronary heart disease, COPD185Diabetes, Asthma185Hypertension, Diabetes, Asthma185Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | | |
| COPDChronic kidney disease, Atrial fibrillation, Heart failure185Atrial fibrillation, Heart failure185Hypertension, COPD185Coronary heart disease, COPD185Coronary heart disease, COPD185Diabetes, Asthma185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Diabetes, Stroke and TIA175Diabetes, COPD170 | | 190 |
| Chronic kidney disease, Atrial fibrillation, Heart failure185Hypertension, Chronic kidney disease, COPD185Hypertension, Coronary heart disease, COPD185Coronary heart disease, COPD185Diabetes, Asthma185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | | |
| Atrial fibrillation, Heart failure | | |
| Heart failureHypertension,185Chronic kidney disease, COPD185Coronary heart disease, COPD185Coronary heart disease, COPD185Diabetes, Asthma185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | - | 185 |
| Hypertension, Chronic kidney disease, COPD185Hypertension, Coronary heart disease, COPD185Goronary heart disease, COPD185Diabetes, Asthma185Hypertension, Diabetes, Asthma180Obesity, Heart failure180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | , | |
| Chronic kidney disease, COPD185Hypertension, Coronary heart disease, COPD185Hypertension, Diabetes, Asthma185Hypertension, Obesity, Heart failure180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | | 105 |
| COPDHypertension,185Coronary heart disease,185COPD185Diabetes,185Diabetes,185Asthma180Obesity,180Heart failure180Diabetes,180Diabetes,180Diabetes,180Diabetes,175Diabetes,175Diabetes,175Diabetes,170 | | 185 |
| Hypertension, Coronary heart disease, COPD185Hypertension, Diabetes, Asthma185Hypertension, Obesity, Heart failure180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA175Diabetes, COPD170 | | |
| Coronary heart disease, COPD185Hypertension, Diabetes, Asthma185Hypertension, Obesity, Heart failure180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, Stroke and TIA180Hypertension, Diabetes, COPD175Diabetes, COPD170 | | 405 |
| COPDHypertension,185Diabetes,185Asthma180Hypertension,180Obesity,180Heart failure180Hypertension,180Diabetes,180Stroke and TIA175Hypertension,175Diabetes,170 | | 185 |
| CordHypertension,185Diabetes,180Asthma180Obesity,180Heart failure180Hypertension,180Diabetes,180Stroke and TIA175Diabetes,175Diabetes,175Diabetes,170 | • | |
| Jiabetes,AsthmaHypertension,180Obesity,Heart failureHypertension,180Diabetes,Stroke and TIAHypertension,175Diabetes,COPDDiabetes,170 | 2015 | 105 |
| AsthmaHypertension,180Obesity,180Heart failure180Hypertension,180Diabetes,180Stroke and TIA175Diabetes,175Diabetes,175Diabetes,170 | | 105 |
| Hypertension,180Obesity,180Heart failure180Hypertension,180Diabetes,180Stroke and TIA175Hypertension,175Diabetes,0COPD170 | | |
| Obesity, Heart failure180Hypertension,180Diabetes,180Stroke and TIA175Hypertension,175Diabetes,170Diabetes,170 | | 120 |
| Heart failureHypertension,180Diabetes,180Stroke and TIA175Hypertension,175Diabetes,2000COPD170 | | 100 |
| Hypertension,180Diabetes,180Stroke and TIA175Hypertension,175Diabetes,170Diabetes,170 | | |
| Diabetes, Stroke and TIA Hypertension, 175 Diabetes, COPD Diabetes, 170 | | 180 |
| Stroke and TIAHypertension,175Diabetes,175COPD170 | | 100 |
| Hypertension,175Diabetes,175COPD170 | | |
| Diabetes, COPD Diabetes, 170 | | 175 |
| COPDDiabetes,170 | | |
| Diabetes, 170 | | |
| | | 170 |
| Chronicklaney alsease. | Chronic kidney disease, | |
| Coronary heart disease | • | |
| Chronic kidney disease, 155 | | 155 |
| Coronary heart disease, | - | |
| Atrial fibrillation | | |

| Triad combination | Count of patients |
|---|-------------------------|
| Hypertension, Chronic kidney disease, Cancer | 155 |
| Hypertension, Diabetes, Heart failure | 150 |
| Chronic kidney disease, Coronary heart disease, Heart failure | 145 |
| Hypertension, Chronic kidney disease, Asthma | 140 |
| Coronary heart disease, Atrial fibrillation, Heart failure | 140 |
| Obesity, Chronic kidney disease, Coronary heart disease | 130 |
| Hypertension, Diabetes, Cancer | 130 |
| Hypertension, Coronary heart disease, Cancer | 130 |
| Obesity, Diabetes, Asthma | 125 |
| Obesity, Chronic kidney disease, Atrial fibrillation | 125 |
| Hypertension, Chronic kidney disease, Dementia | 125 |
| Obesity, Diabetes, Atrial fibrillation | 125 |

| Triad combination | Count of patients |
|-------------------------|-------------------------|
| Obesity, | 120 |
| Atrial fibrillation, | |
| Heart failure | |
| Hypertension, | 120 |
| Atrial fibrillation, | |
| COPD | |
| Diabetes, | 110 |
| Chronic kidney disease, | |
| Atrial fibrillation | 105 |
| Obesity, | 105 |
| Diabetes, | |
| COPD | 105 |
| Hypertension, | 102 |
| COPD, Heart failure | |
| Chronic kidney disease, | 105 |
| Atrial fibrillation, | 105 |
| Stroke and TIA | |
| Obesity, | 105 |
| Chronic kidney disease, | 100 |
| Heart failure | |
| Diabetes, | 105 |
| Chronic kidney disease, | |
| Heart failure | |
| Obesity, | 105 |
| Asthma, | |
| COPD | |
| Obesity, | 100 |
| Coronary heart disease, | |
| Atrial fibrillation | |
| Hypertension, | 100 |
| Stroke and TIA, | |
| Heart failure | |
| Hypertension, | 100 |
| Coronary heart disease, | |
| Asthma | |